Advertisement

Spotlight Series on Hepatitis C

News

Hepatitis C Research Preview for The Liver Meeting 2016

November 8, 2016

Here's a look at some of the noteworthy hepatitis C (HCV) research being presented at The Liver Meeting 2016 in Boston from Nov. 11 to 15. The conference will gather hepatologists from around the world and feature some of the latest research and developments in the field of hepatitis C.

Take a sneak peak at some conference highlights:


Improving Testing, Care and Cure of Hepatitis C in the United States

Researchers will present updates on a program and care model known as ECHO (Extension for Community Healthcare Outcomes), which aims to improve health outcomes in communities. The session will highlight the effectiveness of the ECHO model and how it can help improve hepatitis C care around the world. Specifically, the presenters will describe how to start a new ECHO project and where to obtain resources and technical assistance.


Hepatitis C: Treatment Challenges in the DAA Era

This session will give a "state-of-the-art" update on providing care for the more challenging communities living with hepatitis C by discussing clinical data and offering practical tips on patient management and best treatment options in the direct-acting antiviral (DAA) era. The presenters will help identify optimal treatment, particularly for patients with chronic kidney disease and those who inject drugs, and suggest how to improve cure rates.


Advertisement

Medicaid and Access to Hepatitis C Medications: A Panel Discussion

Even though we have highly effective direct-acting antivirals that can cure hepatitis C, accessing and prescribing these medications can be a major obstacle to care, particularly due to restrictions set by many state Medicaid providers. This panel will bring together different stakeholders to discuss how to help resolve this problem.


Other Notable Studies

Here are some other notable studies from the abstracts book:

  • 19. Incidence and Pattern of "De Novo" Hepatocellular Carcinoma in HCV Patients Treated With Oral DAAs.
  • 20. Uptake of and Factors Associated With Direct-Acting Antiviral Therapy Among Patients Infected With Hepatitis C Virus in the Chronic Hepatitis Cohort Study, 2014-2015.
  • 34. Not Just What, But Also When You Eat: Analyzing the Impact of Meal Timing Patterns on Non-Alcoholic Fatty Liver Disease.
  • 55. Decreasing Mortality in Hepatitis C Patients Awaiting Liver Transplantation in the Direct-Acting Antiviral Era.
  • 111. RG-101 in Combination With 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High SVR Rates in Treatment Naive Genotype 1 and 4 Chronic Hepatitis C Patients.
  • 180. Hepatitis C Complications: Prevalence and Disparities in a Large U.S. Cohort 2006-2014.
  • 227. Towards Eradication of Hepatitis C Virus Infection in the Veterans Affairs National Health Care System: A Study of 107,079 Antiviral Treatment Regimens Administered From 1999-2015.

Check back during and after the conference for our news and analysis.

Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.


Copyright © 2016 Remedy Health Media, LLC. All rights reserved.




This article was provided by TheBodyPRO.com. It is a part of the publication The Liver Meeting.

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.